Press Releases

12/04/2018 OSE Immunotherapeutics Announces Evolution in Company’s Board of Directors and Management

05/04/2018 OSE Immunotherapeutics to Host Conference Call on April 5, 2018

04/04/2018 Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership

28/03/2018 OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances

27/03/2018 OSE IMMUNOTHERAPEUTICS ANNOUNCES PARTICIPATION AT THE H.C. WAINWRIGHT 2018 CONFERENCE

19/03/2018 OSE Immunotherapeutics to Present New Data on OSE-172 at ACCR 2018

15/03/2018 OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi®

28/02/2018 OSE Immunotherapeutics Presenting at the Annual International Conference BIO-EUROPE SPRING

27/02/2018 OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi®

25/01/2018 OSE Immunotherapeutics Receives Notice of Allowance for New Patent for Tedopi®

04/01/2018 OSE Immunotherapeutics to present at Biotech Showcase™ 2018 Conference

03/01/2018 OSE Immunotherapeutics Announces Appointment of Gérard Tardy as Chairman of Company’s Board of Directors

19/12/2017 OSE Immunotherapeutics Presents New Data Analysis of OSE-127 in IBD

14/12/2017 OSE Immunotherapeutics Receives a Grant from French Government Program

07/12/2017 OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi®

26/10/2017 O SE Immunotherapeutics Present ing at the 23rd Annual International Partnering Conference BIO EUROPE®

19/10/2017 OSE Immunotherapeutics Publishes New Data on FR104

02/10/2017 OSE Immunotherapeutics Presents New Data of Myeloid Checkpoint Inhibitor OSE-172

1 2 3 4 5 6 7 8 9 10 11 12 13 14